Cargando…

In Vivo Screen Identifies Liver X Receptor Alpha Agonism Potentiates Sorafenib Killing of Hepatocellular Carcinoma

Detalles Bibliográficos
Autores principales:	VÁZQUEZ SALGADO, A. M., PREZIOSI, M. E., YIN, D., HOLCZBAUER, A., ZAHM, A. M., EREZ, N., KIECKHAEFER, J., ACKERMAN, D., GADE, T. P., KAESTNER, K. H., WANGENSTEEN, K. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481113/ https://www.ncbi.nlm.nih.gov/pubmed/36117551 http://dx.doi.org/10.1016/j.gastha.2022.05.014

Ejemplares similares

Cellular origins of regenerating liver and hepatocellular carcinoma
por: Holczbauer, Ágnes, et al.
Publicado: (2021)

Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR
por: Shao, Weiqing, et al.
Publicado: (2019)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities
por: Sequera, Celia, et al.
Publicado: (2022)

The Dynamic Chromatin Architecture of the Regenerating Liver
por: Wang, Amber W., et al.
Publicado: (2019)

Molecular mechanism of agonism and inverse agonism in ghrelin receptor
por: Qin, Jiao, et al.
Publicado: (2022)

Biased agonism
por: Kenakin, Terry
Publicado: (2009)

Agonizing Hedgehog
por: Weitzman, Jonathan B
Publicado: (2002)

Agon : ballet for twelve dancers
por: Stravinsky, Igor, 1882-1971
Publicado: (1957)

Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells
por: Elmelund, Emilie, et al.
Publicado: (2022)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells
por: Lin, Yi-Te, et al.
Publicado: (2015)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Woman with agonal breathing
por: Hsu, Chien‐Te, et al.
Publicado: (2023)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Evolving role of Sorafenib in the management of hepatocellular carcinoma
por: Ziogas, Ioannis A, et al.
Publicado: (2017)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Connecting inflammation with glutamate agonism in suicidality
por: Erhardt, Sophie, et al.
Publicado: (2013)

Kinetic basis of partial agonism at NMDA receptors
por: Kussius, Cassandra L, et al.
Publicado: (2009)

A structural mechanism of nuclear receptor biased agonism
por: Nemetchek, Michelle D., et al.
Publicado: (2022)

Agonism and Antagonism at the Insulin Receptor
por: Knudsen, Louise, et al.
Publicado: (2012)

Necessity, Entailment, Shared Agonism
por: Smith, Dominic
Publicado: (2021)

Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma
por: Wild, Aaron T., et al.
Publicado: (2013)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Side Chain Orientation of Tryptophan Analogues Determines Agonism and Inverse Agonism in Short Ghrelin Peptides
por: Nicke, Lennart, et al.
Publicado: (2019)

Biased agonism: the quest for the analgesic holy grail
por: Stanczyk, M. Alexander, et al.
Publicado: (2018)

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
por: Cabral, Loraine Kay D., et al.
Publicado: (2020)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions
por: Ray, Emily M, et al.
Publicado: (2017)

The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization
por: Liu, Lei, et al.
Publicado: (2016)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

The role of kinetic context in apparent biased agonism at GPCRs
por: Klein Herenbrink, Carmen, et al.
Publicado: (2016)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
por: Barbier, L., et al.
Publicado: (2011)

Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects
por: Afifi, Ahmed M, et al.
Publicado: (2019)

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
por: Tesori, Valentina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d7mrqfvb5bu3rekp955ebv0hec